Public Market Listing
688520 SSE
SSE primary exchange listing
External market data link · No third-party exchange redistribution
Assets (3 total) 3 Total Assets
0 Approved
2 Phase 3 / Filed
1 Phase 1–2 / Early
5 Diseases
Disease: All diseases (3) Non-Small Cell Lung Cancer (2) Multiple Myeloma (1) Systemic Lupus Erythematosus (1) IgA Nephropathy (1) Amyloidosis (1)
Stage: All stages (3) Approved / Phase 4 (0) Phase 3 / Filed (2) Phase 2 Phase 1 / Preclinical
Quick filter: All (3) Non-Small Cell Lung Cancer (2) Multiple Myeloma (1) Systemic Lupus Erythematosus (1) IgA Nephropathy (1) Amyloidosis (1)
Showing 3 of 3 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 PD-1 + VEGF Multispecific antibody
Non-Small Cell Lung Cancer
Phase 3 CD38 Biologic (subtype unspecified)
Multiple Myeloma Systemic Lupus Erythematosus IgA Nephropathy Amyloidosis
AL Amyloidosis Phase 2/3 PD-1 / VEGF / TGF-β receptor II (TGFβRII) Multispecific antibody
Non-Small Cell Lung Cancer
Upcoming events (12 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2027 (7) April 2027 (2) SCTC21C Phase 1/2 Systemic Lupus Erythematosus (SLE) Est. primary completion 2027-04 ·
NCT07538154 ·
CT.gov ↗ What to watch
SCTB41 Phase 1/2 Advanced Malignant Solid Tumours Est. primary completion 2027-04-30 ·
NCT06600022 ·
CT.gov ↗ What to watch
July 2027 (1) SCTB14 Phase 3 Non-Small Cell Lung Carcinoma (NSCLC) Est. primary completion 2027-07 ·
NCT07362459 ·
CT.gov ↗ What to watch
September 2027 (1) SCTC21C Phase 1/2 IgA Nephropathy Est. primary completion 2027-09 ·
NCT06774664 ·
CT.gov ↗ What to watch
December 2027 (3) SCTC21C Phase 3 Multiple Myeloma (MM) Est. primary completion 2027-12 ·
NCT07297329 ·
CT.gov ↗ What to watch
SCTC21C Phase 3 Amyloidosis Est. primary completion 2027-12 ·
NCT07388602 ·
CT.gov ↗ What to watch
SCTB14 Phase 1/2 Advanced Malignant Solid Tumours Est. primary completion 2027-12-30 ·
NCT06304818 ·
CT.gov ↗ What to watch
2028 (2) September 2028 (1) SCTB41 Phase 1/2 NHL - Non-Hodgkin's Lymphoma Est. primary completion 2028-09-30 ·
NCT07819188 ·
CT.gov ↗ What to watch
October 2028 (1) SCTB41 Phase 2 NSCLC (Advanced Non-small Cell Lung Cancer) Est. primary completion 2028-10 ·
NCT07609251 ·
CT.gov ↗ What to watch
2029 (2) May 2029 (1) SCTB41 Phase 1/2 Advanced Malignant Solid Tumor Est. primary completion 2029-05-30 ·
NCT07594028 ·
CT.gov ↗ What to watch
June 2029 (1) SCTB41 Phase 1/2 Advanced Malignant Solid Tumors Est. primary completion 2029-06-30 ·
NCT07665970 ·
CT.gov ↗ What to watch
2030 (1) January 2030 (1) SCTB41 Phase 2/3 Double Blind Est. primary completion 2030-01-24 ·
NCT07662395 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Financial reports Annual history (2 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $217M $118M — $786M report ↗
View 1 more year Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY — — — — report ↗